Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2-p53 Interaction.Rew, Y., Sun, D., Yan, X., Beck, H.P., Canon, J., Chen, A., Duquette, J., Eksterowicz, J., Fox, B.M., Fu, J., Gonzalez, A.Z., Houze, J., Huang, X., Jiang, M., Jin, L., Li, Y., Li, Z., Ling, Y., Lo, M.C., Long, A.M., McGee, L.R., McIntosh, J., Oliner, J.D., Osgood, T., Saiki, A.Y., Shaffer, P., Wang, Y.C., Wortman, S., Yakowec, P., Ye, Q., Yu, D., Zhao, X., Zhou, J., Medina, J.C., Olson, S.H.
(2014) J.Med.Chem. 57: 10499-10511
- PubMed: 25384157
- DOI: 10.1021/jm501550p
- PubMed Abstract:
Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for th ...
Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 (25), featuring improved potency (KD from ITC competition was 38 pM, SJSA-1 EdU IC50 = 1.6 nM), remarkable pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD). In addition, 25 possesses distinct mechanisms of elimination compared to 1.
Department of Therapeutic Discovery, ‡Department of Pharmaceutics, and §Department of Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.